Pacific Biosciences of California (PACB) 8-K Results of Operations and Financial Condition

Exhibit 99.3

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine-Month Periods Ended September 30,
(in thousands)	2014		2013
Cash flows from operating activities
Net loss	$	(47,185)	$	(62,062)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		3,311		4,238
Amortization of debt discount and financing costs		579		418
Stock-based compensation		6,944		7,361
Other		242		(73)
Changes in assets and liabilities
Accounts receivable		376		(992)
Inventory		(1,348)		171
Prepaid expenses and other assets		85		791
Accounts payable		4,128		425
Accrued expenses		821		544
Deferred service revenue		1,661		56
Deferred contractual revenue		(5,088)		35,000
Other liabilities		(637)		(1,136)
Net cash used in operating activities		(36,111)		(15,259)
Cash flows from investing activities
Purchase of property and equipment		(1,132)		(807)
Purchase of investments		(97,468)		(141,549)
Maturities of investments		119,673		133,391
Net cash provided by (used in) investing activities		21,073		(8,965)
Cash flows from financing activities
Proceeds from issuance of common stock from equity plans		3,319		2,731
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs		20,768		19,954
Proceeds from issuance of Facility Agreement, net of issuance costs		—		19,766
Net cash provided by financing activities		24,087		42,451
Net increase in cash and cash equivalents		9,049		18,227
Cash and cash equivalents at beginning of period		26,362		46,540
Cash and cash equivalents at end of period	$	35,411	$	64,767